Table 1 Baseline characteristics of patients with HBsAg−/HBcAb+ serostatus
Number of patients | 380 |
Mean age (years) | 56.3 ± 12.3 |
Sex (female) | 242 (63.7%) |
Number (%) with disease | |
Rheumatoid arthritis | 272 (71.6%) |
Ankylosing spondylitis | 69 (18.2%) |
Psoriasis/psoriatic arthritis | 39 (10.3%) |
Mean disease duration (years) | |
Rheumatoid arthritis (n = 156) | 8.7 ± 7.1 |
Ankylosing spondylitis (n = 33) | 13.3 ± 9.1 |
Psoriasis/psoriatic arthritis (n = 24) | 11.5 ± 8.8 |
Number (%) using biologic agents | |
Etanercept | 124 (32.6%) |
Adalimumab | 106 (27.9%) |
Golimumab | 63 (16.6%) |
Abatacept | 18 (4.7%) |
Tocilizumab | 16 (4.2%) |
Rituximab | 44 (11.6%) |
Ustekinumab | 8 (2.1%) |
Tofacitinib | 1 (0.3%) |
Number (%) using methotrexate | 250 (65.8%) |
Average dose of methotrexate (mg/week) | 12.8 |
Number (%) using glucocorticoids | 250 (65.8%) |
Average dose of glucocorticoid (mg/day) | 6.3 |
Number (%) using sulfasalazine | 265 (69.7%) |
Number (%) using hydroxychloroquine | 216 (56.8%) |
Number (%) using cyclosporine | 81 (21.3%) |